Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,122.64
(
0.83%
)
US TECH 100
26,138.00
(
1.42%
)
Dow Jones
49,394.61
(
-0.11%
)
Brent Oil
97.19
(
2.29%
)
Bitcoin
79,156.44
(
3.71%
)
News Focus
News Focus
Post# of 257437
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

ciotera

Send PM Follow Ignore
Followers 8
Posts 512
Boards Moderated 0
Alias Born 08/03/2005

ciotera

Re: DewDiligence post# 192414

Friday, 06/12/2015 11:57:41 AM

Friday, June 12, 2015 11:57:41 AM

Post# of 257437
RE: Venetoclax+R

12% CR is too low and 50% relapse after 12m is too high to risk taking a patient off therapy, esp. if they are 17p del. Good thing they bought Imbruvica so that they don't have to compete against it (at least in the US).
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today